Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: The results of AIDS Clinical Trials Group 5068

Journal of Infectious Diseases

Volumn 194, Issue 5, 2006, Pages 623-632

  Jacobson, Jeffrey M ^a,o   Bucy, R Pat ^d   Spritzler, John ^f   Saag, Michael S ^d   Eron Jr , Joseph J ^g   Coombs, Robert W ^h   Wang, Rui ^f   Fox, Lawrence ⁱ   Johnson, Victoria A ^d,e   Cu Uvin, Susan ^k   Cohn, Susan E ^b   Mildvan, Donna ^a   O'Neill, Dorothy ^j   Janik, Jennifer ^c   Purdue, Lynette ⁱ   O'Connor, Deborah K ^l   Di Vita, Christine ^m   Frank, Ian ⁿ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^k BROWN UNIVERSITY   (United States)

^l INDIANA UNIVERSITY   (United States)

^m SANOFI PASTEUR   (France)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC HIV VCP1452 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; UNCLASSIFIED DRUG; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE RETROVIRAL SYNDROME; ADULT; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG INTERMITTENT THERAPY; EPITOPE MAPPING; FEMALE; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA STABILITY; STATISTICAL SIGNIFICANCE; STRUCTURED TREATMENT INTERRUPTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; ANTI-HIV AGENTS; CLINICAL TRIALS; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV; HUMANS; MALE; MIDDLE AGED; RECURRENCE; VIRAL LOAD; VIRAL VACCINES; VIRUS REPLICATION;

EID: 33748078472     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/506364     Document Type: Article

References (33)

1. Hatano H, Vogel S, Yoder C, et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000; 14:1357-63.
2. Saag MS, Hahn BH, Gibbons J, et al. Extensive variation of human immunodeficiency virus type-1 in vivo. Nature 1988; 334:440-4.
3. Johnson WE, Desrosiers RC. Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 2002; 53:499-518.
4. Kerkau T, Bacik I, Bennink JR, et al. The human immunodeficiency virus type 1 (HIV-1) vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class 1 molecules. J Exp Med 1997; 185:1295-305.
5. Schwartz O, Marechal V, Gall SL, et al. Endocytosis of major histocompatibility complex class 1 molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338-42.
6. Howcroft TK, Strebel K, Martin MA, Singer DS. Repression of MHC class 1 gene promoter activity by two-exon Tat of HIV. Science 1993; 260:1320-2.
7. Weinhold KJ, Lyerly HK, Stanley SD, et al. HIV-1 gp120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol 1989; 142:3091-7.
8. + T cells. Nature 2002; 417:95-8.
9. Belshe RB, Gorse GJ, Mulligan MJ, et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998; 12:2407-15.
10. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with RGP120. J Infect Dis 2001; 183:563-70.
11. Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002; 29:254-61.
12. Goepfert PA, Horton H, McElrath MJ, et al. High-dose recombinant canarypox vaccine expressing HIV-1 protein in seronegative human subjects. J Infect Dis 2005; 192:1249-59.
13. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998; 178:70-9.
14. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy ofthe TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003;41:1586-93.
15. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System. J Clin Microbiol 2003; 41:1594-9.
16. Felsenstein J. PHYLIP: phytogeny inference package, version 3.5c. Seattle: University of Washington, 1993.
17. Page RDM. Treeview: an application to display phylogenetic trees on personal computers. Comp Appl Biosci 1996; 12:357-8.
18. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:137-48.
19. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-6.
20. Papasavvas E, Kostman JR, Mounzer K, et al. Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 2004; 1:218-27.
21. Jin X, Ramanathan M, Barsoun S, et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 2002; 76:2206-16.
22. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-43.
23. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy during acute infection. J Infect Dis 2005; 192:607-17.
24. Tubiana R, Carcelain G, Vray M, et al. Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: the Vacciter Study (ANRS 094). Vaccine 2005; 23:4292-301.
25. Levy Y, Gahery-Segard H, Durier C, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-86.
26. Kilby JM, Wang R, Mildvan D, et al. A phase II randomized, partially blinded trial of antiretroviral therapy, HIV-specific immunizations, and IL-2 cycles to promote efficient control of viral replication (ACTG 5024) [abstract 525]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston, MA). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005:243.
27. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-13.
28. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002; 99:13747-52.
29. 3. J Acquir Immune Defic Syndr 2004; 36:791-9.
30. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006; 20:405-13.
31. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
32. Yerly S, Farard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Swiss HIV Cohort Study. Antivir Ther 2003; 8:411-5.
33. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor pop-ulations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-43.